1. Siegel R, Naishadham MA, Jemal A, et al. Cancer statistics, 2012. CA Cancer J Clin . 2012;62:10–29.
  2. ACOG Practice Bulletin. Clinical management guidelines for obstetricians-gynecologists. Human papillomavirus. Obstet Gynecol . 2005;105(61):905.
  3. Holowaty P, Miller AB, Rohan T, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst . 1999;91:252–258.
  4. Melnikow J, Nuovo J, Willan AR, et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol . 1998;92:727–735.
  5. McIndoe WA, McLean MR, Jones RW, et al. The invasive potential of carcinoma in situ of the cervix. Obstet Gynecol . 1984;64:451–458.
  6. Samlal RA, van der Velden J, Ten Kate FJ, et al. Surgical pathologic factors that predict recurrence in stage IB and IIA cervical carcinoma patients with negative pelvic lymph nodes. Cancer . 1997;80:1234–1240.
  7. Havrilesky LJ, Leath CA, Huh W, et al. Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. Gynecol Oncol . 2004;93:429–434.
  8. Berman ML, Keys H, Creasman W, et al. Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gynecologic Oncology Group study). Gynecol Oncol . 1984;19:8–16.
  9. Vasilev SA, Schlaerth JB. Scalene lymph node sampling in cervical carcinoma: a reappraisal. Gynecol Oncol . 1990;37:120–124.
  10. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med . 2000;132 ...